{"id":"ly3832479","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4650488","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting CDK9, LY3832479 prevents the phosphorylation and activation of RNA polymerase II, leading to a decrease in messenger RNA (mRNA) synthesis and a subsequent reduction in protein production. This mechanism is thought to be beneficial in the treatment of various cancers.","oneSentence":"LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:44.451Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer"},{"name":"Metastatic triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT04427501","phase":"PHASE2, PHASE3","title":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-06-17","conditions":"COVID-19","enrollment":3307},{"nctId":"NCT04634409","phase":"PHASE2","title":"A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-10-29","conditions":"COVID-19","enrollment":1755},{"nctId":"NCT04497987","phase":"PHASE3","title":"A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-02","conditions":"COVID-19, SARS-CoV2","enrollment":1180},{"nctId":"NCT04441931","phase":"PHASE1","title":"A Study of LY3832479 (LY-CoV016) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-06-19","conditions":"Healthy","enrollment":26},{"nctId":"NCT04611789","phase":"PHASE1","title":"A Study of LY3832479 (LY-CoV016) in Healthy Participants 1","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-11-02","conditions":"Healthy","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY-CoV016","Etesevimab"],"phase":"phase_2","status":"active","brandName":"LY3832479","genericName":"LY3832479","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LY3832479 is a small molecule that acts as a selective and potent inhibitor of the cyclin-dependent kinase 9 (CDK9). Used for Metastatic non-small cell lung cancer, Metastatic triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}